| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥4873.1B | ¥4792.8B | +1.7% |
| Operating Income | ¥267.5B | ¥222.1B | +20.5% |
| Ordinary Income | ¥176.1B | ¥140.1B | +25.7% |
| Net Income | ¥183.2B | ¥79.6B | +130.2% |
| ROE | 5.8% | 2.6% | - |
FY2025 Q3 cumulative results show revenue of 487.3B yen (YoY +1.7%), operating income of 26.7B yen (YoY +20.5%), ordinary income of 17.6B yen (YoY +25.7%), and net income of 18.3B yen (YoY +130.2%). The substantial net income growth was significantly influenced by non-recurring factors including special gains of 14.5B yen and fixed asset sale gains of 4.5B yen. Operating profitability improved with operating margin rising to 5.5% from prior period levels, while the company maintains a gross margin of approximately 31.0%. Total assets reached 1,199.9B yen with equity of 314.8B yen, reflecting an equity ratio of 26.2%. The balance sheet exhibits elevated leverage with interest-bearing debt of 469.2B yen and a debt-to-equity ratio of 2.81 times.
Revenue increased 1.7% YoY to 487.3B yen, driven primarily by the Medical Treatment Related segment which generated 393.6B yen in sales (up 3.7% from prior year 374.3B yen), representing the core business at approximately 81% of total sales. The Medicine Related segment contributed 104.5B yen (down 2.1% from prior year 106.8B yen), while the Pharma Packaging segment faced headwinds with sales declining to 45.1B yen from 50.1B yen (down 10.0%). Operating income rose 20.5% to 26.7B yen, with operating margin expanding to 5.5% from 4.6% in the prior year. The Medical Treatment Related segment delivered operating income of 37.5B yen (up 3.1% from 36.4B yen), while Medicine Related improved significantly to 8.8B yen (up 35.8% from 6.5B yen). The Pharma Packaging segment recorded an operating loss of 1.5B yen, deteriorating from a prior year profit of 0.5B yen. Non-recurring factors in the current period include goodwill impairment of 0.7B yen in the Pharma Packaging segment and substantial special gains contributing to the extraordinary jump in net income. The gap between operating income of 26.7B yen and ordinary income of 17.6B yen reflects net non-operating expenses of approximately 9.1B yen, primarily driven by interest expense of 6.9B yen on the company's elevated debt position. The divergence between ordinary income of 17.6B yen and net income of 18.3B yen (pre-tax income of 28.2B yen) resulted from special gains of 14.5B yen, predominantly from fixed asset disposals of 4.5B yen and other investment-related gains. This represents a revenue up/profit up pattern, though the magnitude of net income growth is substantially inflated by non-recurring special items.
The Medical Treatment Related segment serves as the core business, contributing 81% of total segment sales with revenue of 393.6B yen and operating income of 37.5B yen, delivering an operating margin of 9.5%. This segment demonstrated stable growth with sales increasing 3.7% YoY and operating income expanding 3.1%. The Medicine Related segment generated 104.5B yen in revenue with operating income of 8.8B yen, achieving an 8.4% operating margin and showing strong profit growth of 35.8% despite a modest 2.1% revenue decline. The Pharma Packaging segment faced operational challenges, with revenue declining 10.0% to 45.1B yen and swinging to an operating loss of 1.5B yen from a prior year profit of 0.5B yen. This segment recorded a goodwill impairment charge of 0.7B yen during the period, indicating potential structural issues requiring monitoring. Material margin differences exist across segments, with Medical Treatment and Medicine Related both operating profitably above 8% margins while Pharma Packaging operates at negative margins, suggesting the need for strategic review of this underperforming division.
[Profitability] Operating margin reached 5.5% in Q3 FY2025, improving from 4.6% in the prior year, while net profit margin stands at 3.4%. ROE of 5.3% remains modest, matching the industry median of 5.2%, while ROA of 1.4% falls below the industry median of 3.3%, reflecting lower asset efficiency. ROIC estimated at 2.6% significantly underperforms the industry median of 6.0%, indicating room for improvement in capital allocation efficiency. [Cash Quality] Cash and deposits of 112.4B yen provide coverage of 0.59 times against short-term debt of 189.5B yen, warranting monitoring of short-term liquidity. Working capital metrics show deterioration with receivables turnover at 129 days (vs industry median 83 days) and inventory turnover extended to 284 days (vs industry median 109 days), significantly exceeding industry norms and indicating operational inefficiencies. Operating working capital cycle stands at 413 days compared to industry median of 108 days. [Investment Efficiency] Asset turnover of 0.41 times underperforms the industry median of 0.58 times, reflecting the impact of goodwill increases and working capital accumulation. [Financial Health] Equity ratio of 26.2% substantially trails the industry median of 63.8%, reflecting elevated leverage. Current ratio of 136.5% compares unfavorably to the industry median of 283%, though remains above 100%. Debt-to-equity ratio of 2.81 times significantly exceeds the industry median financial leverage of 1.53 times, indicating heightened financial risk. Interest coverage ratio stands at 3.86 times.
Cash and deposits increased 10.3B yen YoY to 112.4B yen, though this growth trails the 18.3B yen net income, suggesting cash conversion challenges. Working capital deterioration is evident with trade receivables expanding 11.7B yen to 172.0B yen and inventories increasing 14.3B yen to 179.3B yen, collectively absorbing approximately 26.0B yen in operating cash that would otherwise support liquidity. Accounts payable increased 6.2B yen to 126.6B yen, providing partial offset through extended supplier credit. The substantial increases in goodwill (23.4B yen) and intangible assets (21.7B yen) suggest significant investing activities related to M&A transactions, though these are non-cash balance sheet reclassifications at acquisition. Interest-bearing debt rose 18.8B yen to 469.2B yen, indicating continued reliance on external financing. The company's short-term debt of 189.5B yen against cash of 112.4B yen results in a coverage ratio of 0.59 times, indicating potential refinancing pressure. Overall cash position growth of 10.3B yen appears constrained by working capital absorption and debt servicing requirements, with the cash-to-short-term-liabilities coverage warranting close monitoring.
Ordinary income of 17.6B yen versus operating income of 26.7B yen reflects a negative non-operating contribution of approximately 9.1B yen, primarily comprising interest expense of 6.9B yen and foreign exchange losses, representing 1.9% of revenue. The substantial gap between ordinary income of 17.6B yen and pre-tax income of 28.2B yen stems from special gains of 14.5B yen, with fixed asset sale gains of 4.5B yen serving as the primary component. Non-operating and special items collectively contributed 10.6B yen to pre-tax income, representing 58% of the 18.3B yen net income, indicating significant non-recurring support. Special gains represent 3.0% of revenue, concentrated in one-time asset disposals and investment-related items. The reliance on non-recurring items to achieve the 130.2% net income growth raises concerns about underlying earnings sustainability. Core operating performance shows more modest improvement with operating income up 20.5%, suggesting normalized earnings power remains constrained. Without disclosed operating cash flow data, the cash quality of reported earnings cannot be fully validated, though the working capital deterioration (extended receivables and inventory days) suggests potential divergence between accrual earnings and cash generation.
The company forecasts full-year revenue of 677.0B yen, operating income of 37.0B yen, ordinary income of 24.2B yen, and net income of 13.0B yen. Q3 cumulative progress rates show revenue achievement at 72.0%, operating income at 72.3%, ordinary income at 72.8%, and net income at 141.2% of full-year guidance. Revenue and operating income progress track slightly below the standard 75% benchmark for Q3, suggesting Q4 will require accelerated performance to meet targets. The extraordinary net income progress of 141.2% reflects the aforementioned special gains of 14.5B yen, which will not recur in Q4, implying Q4 net income may decline sequentially. The company projects YoY changes of revenue +5.0%, operating income +39.1%, and ordinary income +123.7%, with the substantial ordinary income growth reflecting comparison against a weak prior year base. The guidance implies Q4 operating margin compression from Q3 levels, requiring validation of whether seasonal factors or cost pressures are anticipated.
Annual dividend is projected at 18.0 yen per share, comprising an interim dividend of 12.0 yen and forecasted year-end dividend of 13.0 yen. Based on full-year net income guidance of 13.0B yen and basic EPS forecast of 79.4 yen, the payout ratio calculates to approximately 22.7%, representing a conservative level. However, using Q3 cumulative net income of 18.3B yen yields a trailing payout ratio of approximately 25.7%. The dividend appears sustainable from an earnings perspective, though validation requires confirmation of free cash flow adequacy given the working capital deterioration and elevated capital expenditure requirements typical in the manufacturing sector. With cash reserves of 112.4B yen against projected annual dividends of approximately 2.9B yen (based on shares outstanding), near-term dividend coverage appears adequate. No share buyback activities are disclosed in the available data. The total return ratio equals the payout ratio at approximately 23-26% given the absence of repurchases, indicating substantial cash retention for debt reduction or reinvestment needs.
Working capital deterioration represents a critical risk, with receivables turnover at 129 days and inventory turnover at 284 days significantly exceeding industry medians of 83 days and 109 days respectively, absorbing approximately 26.0B yen in operating cash over the past year. This trend constrains cash generation and increases reliance on external financing. High financial leverage with debt-to-equity ratio of 2.81 times and equity ratio of 26.2% (versus industry median 63.8%) creates vulnerability to interest rate increases and refinancing risk, particularly given short-term debt of 189.5B yen represents 40.4% of total borrowings. Current interest expense of 6.9B yen consumes 25.8% of operating income, limiting financial flexibility. Goodwill and intangible asset increases totaling 45.1B yen to 94.8B yen (representing 7.9% of total assets) create impairment risk if acquisition synergies fail to materialize, as evidenced by the 0.7B yen goodwill impairment already recognized in Pharma Packaging segment.
[Industry Position] (Reference - Proprietary Analysis) The company's profitability metrics align with or trail industry medians across key measures. Operating margin of 5.5% significantly underperforms the manufacturing industry median of 8.7% (IQR: 5.1%-12.6%), placing the company in the lower quartile and indicating competitive disadvantage or business mix challenges. Net profit margin of 3.4% falls below the industry median of 6.4% (IQR: 3.3%-9.3%), though remains within the interquartile range. ROE of 5.3% matches the industry median of 5.2%, though this parity results from elevated financial leverage of 3.81 times versus industry median of 1.53 times, implying underlying operational ROA underperformance. The company's equity ratio of 26.2% substantially trails the industry median of 63.8%, positioning in the bottom decile and reflecting aggressive capital structure. Asset turnover of 0.41 times underperforms the industry median of 0.58 times, indicating inefficient asset utilization exacerbated by working capital accumulation. Current ratio of 136.5% falls well below the industry median of 283%, suggesting constrained liquidity buffers. Working capital metrics show pronounced deterioration with receivables days of 129 versus industry median 83, inventory days of 284 versus median 109, and operating working capital cycle of 413 days versus median 108 days, representing significant outlier underperformance. Revenue growth of 1.7% trails the industry median of 2.8%, though remains positive. The company's financial profile reflects a highly leveraged manufacturer with below-median profitability, asset efficiency, and liquidity, offset partially by industry-median ROE achieved through financial engineering rather than operational excellence. (Industry: Manufacturing sector, n=100 companies, Comparison: 2025-Q3 period, Source: Proprietary analysis)
Operating performance shows genuine improvement with operating income growth of 20.5% and margin expansion to 5.5%, though profitability remains below industry standards and constrained by elevated interest expense of 6.9B yen. The Medical Treatment Related segment demonstrates stable core business characteristics contributing 81% of revenue with 9.5% operating margins, while structural challenges in Pharma Packaging require strategic resolution. The 130.2% net income growth headline significantly overstates sustainable earnings power, as 58% of pre-tax income derived from non-recurring special gains of 14.5B yen, primarily asset disposals. Normalized earnings trajectory appears more aligned with the 20-26% operating and ordinary income growth rates. Working capital management deterioration presents a critical concern, with receivables and inventory absorption of 26.0B yen constraining cash generation and creating a 413-day operating cycle that ranks as a significant industry outlier. Financial structure sustainability warrants monitoring given debt-to-equity of 2.81 times, equity ratio of 26.2%, and short-term debt coverage ratio of 0.59 times, though dividend payout ratio of 23-26% provides cushion for deleveraging. The 45.1B yen increase in goodwill and intangibles to 94.8B yen requires ongoing impairment assessment, with the 0.7B yen charge in Pharma Packaging serving as an early warning indicator.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.